[AGRX] Agile Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 200.03 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 6.62 Change: 0.07 (1.07%)
Ext. hours: Change: 0 (0%)

chart AGRX

Refresh chart

Description: Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding28.74 M EPS-1 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.67
P/E To EPS Growth P/S P/BV4.1 Price/Cash Per Share
Price/Free Cash Flow-13.7 ROA-37.05% ROE-52.21% ROI
Current Ratio11.29 Quick Ratio Long Term Debt/Equity0.31 Debt Ratio0.1
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities19.52 M Cash From Investing Activities-190 K Cash From Operating Activities-5.65 M Gross Profit
Net Profit-8.54 M Operating Profit-8.01 M Total Assets68.7 M Total Current Assets54.36 M
Total Current Liabilities4.81 M Total Debt15.12 M Total Liabilities19.94 M Total Revenue
Technical Data
High 52 week5.37 Low 52 week2.04 Last close3.28 Last change1.86%
RSI30.73 Average true range0.43 Beta0.89 Volume99.56 K
Simple moving average 20 days-4.15% Simple moving average 50 days-22.43% Simple moving average 200 days-16.6%
Performance Data
Performance Week15.49% Performance Month-32.51% Performance Quart-38.23% Performance Half-17.59%
Performance Year28.13% Performance Year-to-date21.93% Volatility daily14.71% Volatility weekly32.9%
Volatility monthly67.42% Volatility yearly233.55% Relative Volume435.39% Average Volume499.87 K
New High New Low


2020-05-11 16:05:10 | Agile Therapeutics to Participate in Virtual Fireside Chat as part of the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020

2020-05-07 08:36:12 | Is the Options Market Predicting a Spike in Agile Therapeutics AGRX Stock?

2020-05-06 20:19:45 | Edited Transcript of AGRX earnings conference call or presentation 5-May-20 8:30pm GMT

2020-05-05 16:01:10 | Agile Therapeutics Reports First Quarter 2020 Financial Results

2020-05-04 12:07:00 | Why Agile Therapeutics Stock Is Jumping Today

2020-04-23 07:30:10 | Agile Therapeutics to Host First Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, May 5, 2020

2020-04-22 08:00:10 | Agile Therapeutics Announces Changes to its Board of Directors

2020-04-01 17:50:09 | Agile Therapeutics AGRX Flat As Market Sinks: What You Should Know

2020-03-23 16:31:20 | Agile Therapeutics AGRX Stock Remains a Top Pick, Says Analyst

2020-03-18 08:49:12 | Implied Volatility Surging for Agile Therapeutics AGRX Stock Options

2020-03-15 16:02:02 | Weekly CFO Buys Highlight

2020-03-03 15:00:20 | 7 Cheap Stocks Under $7 With Massive Upside Potential

2020-02-25 11:41:43 | Agile Therapeutics, Inc. Nasdaq: AGRX to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020

2020-02-21 12:00:05 | Agile Therapeutics AGRX Upgraded to Buy: Here's Why

2020-02-21 11:30:04 | Is Agile Therapeutics AGRX Stock Outpacing Its Medical Peers This Year?

2020-02-21 08:35:10 | Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock

2020-02-21 07:46:22 | The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

2020-02-20 16:14:47 | Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

2020-02-20 16:01:10 | Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-14 18:46:11 | FDA Approves Agile Therapeutics, Inc.’s Twirla® levonorgestrel and ethinyl estradiol Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

2020-02-12 09:18:32 | The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

2020-02-11 08:46:08 | Agile Finalizes $35M Term Loan Facility As Twirla PDUFA Date Looms

2020-02-10 16:30:10 | Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors

2020-02-03 13:30:16 | Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

2020-01-10 09:33:02 | The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

2020-01-09 06:19:11 | Buy Multibagger Stocks as Odds of a Rally Are High in 2020

2020-01-07 10:22:22 | The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold

2020-01-06 08:14:45 | Here's How to Play Stocks as US-Iran Tensions Mount

2020-01-06 08:00:10 | Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

2020-01-03 07:55:22 | The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

2020-01-02 08:00:10 | Agile Therapeutics Strengthens Commercial Leadership Team

2019-12-23 08:36:01 | Implied Volatility Surging for Agile Therapeutics AGRX Stock Options

2019-12-19 16:05:10 | Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco

2019-12-14 18:59:54 | Hedge Funds Have Never Been More Bullish On Agile Therapeutics Inc AGRX

2019-11-15 10:09:21 | The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

2019-11-14 16:30:00 | Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

2019-11-11 16:40:43 | RBC: 3 Stock Picks Set to Soar 30%+

2019-11-05 06:53:31 | The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

2019-11-04 11:24:17 | Agile AGRX Stock Surges Over 370%, What’s Next?

2019-10-31 13:11:00 | Agile Therapeutics' stock rockets nearly 4-fold after contraceptive patch Twirla gets favorable FDA committee nod

2019-10-31 10:52:11 | Agile Therapeutics Rallies After FDA Panel Backs Contraceptive Patch

2019-10-31 08:34:49 | Benzinga Pro's Top 5 Stocks To Watch For Thurs., Oct. 31, 2019: AAPL, FB, AGRX, X, CROX

2019-10-30 18:33:10 | Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® AG200-15

2019-10-29 17:24:30 | Agile AGRX: Should You Catch this Falling Knife?

2019-10-29 07:32:34 | The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

2019-10-28 08:00:05 | Agile Therapeutics Reports Third Quarter 2019 Financial Results

2019-10-25 09:30:01 | Is Agile Therapeutics AGRX Outperforming Other Medical Stocks This Year?

2019-10-25 09:00:01 | Agile Therapeutics AGRX Upgraded to Buy: Here's What You Should Know

2019-10-24 15:57:22 | 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts

2019-10-14 00:17:21 | 3 Top Biotech Stocks With Major Catalysts in October